As of 2024-12-13, the Relative Valuation of Abionyx Pharma SA (ABNX.PA) is (1.43) EUR. This relative valuation is based on P/E multiples. With the latest stock price at 1.28 EUR, the upside of Abionyx Pharma SA based on Relative Valuation is -211.6%.
The range of the Relative Valuation is (1.28) - (1.58) EUR.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 13.2x - 16.3x | 14.8x |
| Forward P/E multiples | 13.2x - 16.3x | 14.8x |
| Fair Price | (1.28) - (1.58) | (1.43) |
| Upside | -200.0% - -223.2% | -211.6% |
| Date | P/E |
| 2024-12-06 | -13.03 |
| 2024-12-05 | -12.93 |
| 2024-12-04 | -13.22 |
| 2024-12-03 | -13.55 |
| 2024-12-02 | -13.18 |
| 2024-11-29 | -13.94 |
| 2024-11-28 | -13.94 |
| 2024-11-27 | -12.87 |
| 2024-11-26 | -13.07 |
| 2024-11-25 | -13.14 |
| 2024-11-22 | -12.60 |
| 2024-11-21 | -12.87 |
| 2024-11-20 | -13.34 |
| 2024-11-19 | -13.63 |
| 2024-11-18 | -13.67 |
| 2024-11-15 | -13.80 |
| 2024-11-14 | -13.94 |
| 2024-11-13 | -14.04 |
| 2024-11-12 | -13.94 |
| 2024-11-11 | -14.02 |
| 2024-11-08 | -13.92 |
| 2024-11-07 | -14.25 |
| 2024-11-06 | -14.35 |
| 2024-11-05 | -14.06 |
| 2024-11-04 | -12.91 |
| 2024-11-01 | -12.99 |
| 2024-10-31 | -12.93 |
| 2024-10-30 | -12.62 |
| 2024-10-29 | -12.56 |
| 2024-10-28 | -12.74 |
| 2024-10-25 | -12.91 |
| 2024-10-24 | -12.58 |
| 2024-10-23 | -12.66 |
| 2024-10-22 | -12.81 |
| 2024-10-21 | -12.00 |
| 2024-10-18 | -12.14 |
| 2024-10-17 | -12.35 |
| 2024-10-16 | -12.54 |
| 2024-10-15 | -12.37 |
| 2024-10-14 | -12.56 |
| 2024-10-11 | -12.68 |
| 2024-10-10 | -12.74 |
| 2024-10-09 | -12.78 |
| 2024-10-08 | -12.87 |
| 2024-10-07 | -12.72 |
| 2024-10-04 | -12.78 |
| 2024-10-03 | -12.68 |
| 2024-10-02 | -12.68 |
| 2024-10-01 | -12.83 |
| 2024-09-30 | -12.83 |